gene editing
Bayer trumpets $1bn CRISPR deal with Mammoth Bio
Phil Taylor
Bayer, CRISPR, gene editing, hepatology, Mammoth Biosciences, partnering
0 Comment
Vertex builds in gene editing yet again, with $1.2bn Arbor deal
Phil Taylor
Arbor Biotechnologies, beta thalassaemia, CRISPR/Cas9, gene editing, sickle cell disease, type 1 diabetes, Vertex Pharma
0 Comment
Intellia, Regeneron ace first trial with ‘in vivo’ CRISPR drug
Phil Taylor
ATTR amyloidosis, CRISPR/Cas9, gene editing, Intellia Therapeutics, rare disease, Regeneron
0 Comment
Nobel winner Charpentier’s CRISPR Therapeutics gets $900m in reworked Vertex deal
Richard Staines
CRISPR, CRISPR Therapeutics, Editas, gene editing, Vertex
0 Comment
Vertex eyes controllable genetic drugs with $1.3bn Obsidian alliance
Phil Taylor
CRISPR Therapeutics, CRISPR/Cas9, gene editing, Obsidian Therapeutics, partnering, Vertex Pharma
0 Comment
R&D/ Views & Analysis/ Views and analysis
Casting aside CRISPR scissors and making a point with base editors
mike.hammerton@pharmaphorum.com
CRISPR, gene editing, immune cell therapy, Kymriah, Perkin Elmer, Yescarta
0 Comment
R&D/ Views & Analysis/ Views and analysis
Gene editing: beyond the hype
George Underwood
CAR, CAR-Tregs, cell and gene therapy, cell therapy, CRISPR, gene editing, gene therapy, JP Morgan, Sangamo
0 Comment
ASH: CRISPR, Vertex’ CTX001 hits the mark in red cell disorders
Phil Taylor
beta thalassaemia, CRISPR Therapeutics, CRISPR/Cas9, gene editing, sickle cell disease, Vertex Pharma
0 Comment